Literature DB >> 33106929

Biologic therapy in Sjögren's syndrome.

Qin Shao1.   

Abstract

Sjögren's syndrome (SS) is a chronic autoimmune disease with complex and diverse clinical manifestations. It is characterized by lymphocyte infiltration of exocrine glands such as the salivary gland and lacrimal gland leading to insufficient secretion of the gland, manifested as dry mouth and dry eyes. In addition, it can involve extraglandular organs and cause systemic damage. The pathogenesis of SS is still unclear. At present, symptomatic treatment is the mainstay and there is a lack of effective therapy. With the development of molecular pathways underlying the pathogenesis of SS, more and more novel biological agents are used to treat SS. We summarized and analyzed the existing evidences on the efficacy of biological treatment of SS and their targets. Analysis of the efficacy of biological therapy and improvement of treatment strategies can help to give full play to its therapeutic advantages.

Entities:  

Keywords:  Biologic therapy; Clinical trial; Sjögren’s syndrome

Mesh:

Year:  2020        PMID: 33106929     DOI: 10.1007/s10067-020-05429-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  66 in total

1.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

2.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

3.  Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.

Authors:  Maria Sole Chimenti; Marina Talamonti; Lucia Novelli; Miriam Teoli; Marco Galluzzo; Paola Triggianese; Roberto Perricone
Journal:  J Dermatol Case Rep       Date:  2015-09-30

Review 4.  Inflammasome Complexes: Emerging Mechanisms and Effector Functions.

Authors:  Vijay A K Rathinam; Katherine A Fitzgerald
Journal:  Cell       Date:  2016-05-05       Impact factor: 41.582

5.  Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands.

Authors:  M Azuma; K Aota; T Tamatani; K Motegi; T Yamashita; K Harada; Y Hayashi; M Sato
Journal:  Arthritis Rheum       Date:  2000-08

6.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

Authors:  Xavier Mariette; Philippe Ravaud; Serge Steinfeld; Gabriel Baron; Joelle Goetz; Eric Hachulla; Bernard Combe; Xavier Puéchal; Yvon Pennec; Bernard Sauvezie; Aleth Perdriger; Gilles Hayem; Anne Janin; Jean Sibilia
Journal:  Arthritis Rheum       Date:  2004-04

7.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.

Authors:  Vidya Sankar; Michael T Brennan; Marc R Kok; Rose Anne Leakan; Janine A Smith; Joan Manny; Bruce J Baum; Stanley R Pillemer
Journal:  Arthritis Rheum       Date:  2004-07

8.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

9.  Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.

Authors:  Katrine Brække Norheim; Erna Harboe; Lasse G Gøransson; Roald Omdal
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

10.  Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.

Authors:  Trinka Vijmasi; Feeling Y T Chen; Ying Ting Chen; Marianne Gallup; Nancy McNamara
Journal:  Mol Vis       Date:  2013-09-19       Impact factor: 2.367

View more
  1 in total

Review 1.  Cardiovascular Involvement in Sjögren's Syndrome.

Authors:  Fabiola Atzeni; Francesco Gozza; Giacomo Cafaro; Carlo Perricone; Elena Bartoloni
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.